FAX RECEIVED

OCT 17 2002

Atty Docket No. 17682A-005100US

PTO FAX NO.:

703/308-4556 GROUP 1600

ATTENTION: TELEPHONE NO.:

**Examiner Owens** 

OFFICIAL

Group Art Unit 1623

# OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF EXAMINER Owens

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s) in re Application of Charles R. Petrie et al., Application No. 09/693,213, filed October 19, 2000 for CROSS-LINKING OLIGONUCLEOTIDES is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

### Document(s) Attached

Willi Newell

1. Amendment

Number of pages being transmitted, including this page: 3

Dated: 10/16/02

Nikki Newell

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 415-576-0200

Fax: 415-576-0300

Client Ref. No.

TOWNSEND and TOWNSEND and CREW LLP

By Milli Mewell

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Owens

Attorney Docket No.: 17682A

Charles R. Petrie et al.

Art Unit:

1623

Application No.: 09/693,213

**AMENDMENT** 

Filed: October 19, 2000

For: CROSS-LINKING OLIGONUCLEOTIDES

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed July 31, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 21, 22, 27, 28, 36-38 and 42-44 without prejudice.

### REMARKS

In response to the Office Action, and in order to expedite prosecution of this application Applicant is canceling the rejected claims.

Among the claims rejected was claim 29. However, it is believed that its inclusion in the rejection may have been in error since it is dependent on claim 10, which is not directed to a pyrimidine and which was allowed.